Loading…
Loading…
GILD · NASDAQ · Healthcare
“With earnings of $6.84 and a P/E of 20.6, prudent investors must scrutinize whether Gilead's drug pipeline justifies this premium to pharmaceutical industry averages.”
— In the voice of Graham
Project future earnings using analyst estimates and historical growth rates. Model 5-year earnings trajectories.
Market Cap
$175.30B
P/E Ratio
20.60
Forward P/E
—
EPS
$6.84
PEG Ratio
0.86
Book Value
$18.25
Dividend Yield
2.28%
Profit Margin
28.90%
ROE
37.48%
Use the interactive growth projection with pre-loaded data for Gilead Sciences Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for GILD: